|Articles|August 5, 2020
Catalent
Author(s)Catalent Pharma Solutions
Catalent’s next-generation cell line development technology, GPEx® Boost, leverages GPEx platform improvements and a glutamine synthase knock-out CHO cell line, providing the same stability and proven technology of traditional GPEx technology with enhanced benefits, including increased titer for even the most difficult-to-express proteins, improved cell growth and viability, and fewer process steps, resulting in reduced timelines.
Catalent
14 Schoolhouse Road Somerset, NJ 08873 USA
Tel. +1.888.765.8846
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
4
Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
5